Publications by authors named "Xiaru Zhang"
Background: Diabetic kidney disease (DKD) is still as a common chronic micro-vascular complication of type 1 diabetic (T1DM). Although many studies had verified the therapeutic potential of mesenchymal stem cells (MSCs) on the clinical treatment of the related complications associated with T1DM, especially the DKD, by preserving the balances of immune micro-environment and so on. However, the immunomodulatory capabilities of MSCs are still controversial on the the efficacy of DKD treatment primarily due to the variations on the immune micro-environment, which could be modulated by a variety of elements, such as the vitamin D (VD).
View Article and Find Full Text PDFArticle Synopsis
- Mesenchymal stem cells (MSCs) show potential in treating type 1 diabetes mellitus (T1DM) by possibly affecting T cell behavior, but the exact mechanisms are not fully understood.
- The study identified that miR-25, found in MSCs' exosomes, is linked to cell migration and can decrease CXCR3 expression in activated T cells, reducing their movement towards the pancreas.
- In experiments with T1DM mouse models, MSC treatment raised miR-25 levels and reduced T cell numbers in the pancreas, indicating that miR-25 may help prevent T cell infiltration in T1DM.
Objective: Our previous study found that it could significantly increase the expression of IL32 after stimulating the human umbilical cord mesenchymal stem cells (S-HuMSCs). However, its role on the osteogenesis and cranial bone regeneration is still largely unknown. Here, we investigated the possible mechanism of this effect.
View Article and Find Full Text PDFArticle Synopsis
- * Research revealed that an increased expression of the senescence marker gene P53 in DOP hJBMMSCs leads to significant cellular aging, negatively impacting their ability to support bone regeneration.
- * Targeting the P53 gene could restore the osteogenic differentiation ability in DOP hJBMMSCs, suggesting that controlling senescence may provide new treatment strategies for diabetic bone metabolic diseases.